Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information In appraisal
Process STA Standard
ID number 6340

Provisional Schedule

Committee meeting 05 November 2024
Expected publication 29 January 2025

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton


Companies sponsors Merck Sharp & Dohme (molnupiravir)
Others Department of Health and Social Care
  NHS England
  NHS North East and North Cumbria ICB
  NHS South East London ICB
Patient carer groups Action for Pulmonary Fibrosis
  African Caribbean Leukaemia Trust
  Anthony Nolan
  Aplastic Anaemia Trust
  Blood Cancer UK
  Cardiomyopathy UK
  Cardiothoracic Transplant Patient Group
  Chronic Lymphocytic Leukaemia Support Association
  Chronic Myeloid Leukaemia Support Group
  Clinically Vulnerable Families
  Crohn’s & Colitis UK
  Diabetes UK
  Down’s Syndrome Association
  Forgotten Lives UK
  Immunodeficiency UK
  Kidney Care UK
  Kidney Research UK
  Leukaemia Care
  Leukaemia UK
  Long Covid Kids
  Long Covid Physio
  Long Covid Scotland
  Long Covid Support
  Lupus UK
  Lymphoma Action
  Macmillan Cancer Support
  MDS UK Patient Support Group
  Metabolic Support UK
  MS Society
  Multiple Sclerosis Trust
  Myeloma UK
  National Kidney Federation
  National Rheumatoid Arthritis Society
  Polycystic Kidney Disease Charity
  Sarcoidosis UK
  Scleroderma and Raynaud’s UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Thrombosis UK
  Vasculitis UK
Professional groups Association for Clinical Biochemistry & Laboratory Medicine
  Association of British Neurologists
  Association of Cancer Physicians
  British Geriatrics Society
  British HIV Association
  British Infection Association
  British Paediatric Allergy Infection and Immunity Group
  British Society for Allergy & Clinical Immunology
  British Society for Heart Failure
  British Society for Immunology
  British Society for Rheumatology
  British Thoracic Society
  British Transplant Society
  Cancer Research UK
  Faculty of Pharmaceutical Medicine
  Infection Prevention Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for General Microbiology
  UK Clinical Pharmacy Association
  UK CLL Forum
  UK Kidney Association
  UK Renal Pharmacy Group
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Gilead Sciences (remdesivir)
  GlaxoSmithKline (sotrovimab)
  Pfizer (nirmatrelvir plus ritonavir)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Infectious Diseases Group
  Cochrane UK
  Genomics England
  Institute of Cancer Research
  Long Covid Research Initiative
  MRC Clinical Trials Unit
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
12 April 2024 Invitation to participate
06 November 2023 - 04 December 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
06 September 2023 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual